Naotsugu Ichimaru
Research Subjects
Naotsugu Ichimaru has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Shiro Takahara
Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Suita and
2 shared publications- Toyofumi Abe
Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan
2 shared publications - Yoichi Kakuta
Department of Urology The University of Osaka Graduate School of Medicine Suita Osaka Japan
2 shared publications Yukito Kokado
Takahashi Clinic, Toyonaka, Osaka, Japan
2 shared publicationsA Okuyama
Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan
1 shared publicationA. Okuyama
1 shared publication
Latest Publications
- Open Access
- 20 December 2009
- Published by Wiley in International Journal of Urology
- Vol. 17 (1) , 48-54
Post‐transplant lymphoproliferative disorder following renal transplantation: A single‐center experience over 40 years
Objectives: To investigate post‐transplant lymphoproliferative disorder (PTLD) following renal transplantation at our institution.Methods: Medical records of 631 patients who underwent renal transplantation at Osaka University Hospital between March 1965 and December 2008 were reviewed.Results: PTLD following renal transplantation was detected in 10 patients (five men, five women; mean age at transplantation, 38.5 years). Mean duration from renal transplantation to the onset of PTLD was 7.1 years (range, 5 months to 18 years, 9 months). Mean duration of observation was 3.9 years from the onset of PTLD. Immunosuppressant therapy comprised multidrug combination therapy, including cyclosporine in six patients and tacrolimus in four patients. In addition to a reduction in the immunosuppressant dose, which was performed in all patients, PTLD was treated with surgery in seven patients, radiotherapy in two patients, rituximab in five patients, and cytotoxic chemotherapy in four patients. A complete remission in eight patients and progressive disease in two were observed. At last follow up, seven patients were alive and five patients had functioning grafts.Conclusions: The incidence of PTLD following renal transplantation at our institution is 1.6% with onset occurring more than 5 years after transplantation in five patients. Consequently, with long‐term renal graft survival now feasible, attention must be paid to detecting late‐onset PTLD.
- 20 December 2009
- Published by Wiley in International Journal of Urology
- Vol. 17 (1) , 48-54
Open AccessPost‐transplant lymphoproliferative disorder following renal transplantation: A single‐center experience over 40 years
Objectives: To investigate post‐transplant lymphoproliferative disorder (PTLD) following renal transplantation at our institution.Methods: Medical records of 631 patients who underwent renal transplantation at Osaka University Hospital between March 1965 and December 2008 were reviewed.Results: PTLD following renal transplantation was detected in 10 patients (five men, five women; mean age at transplantation, 38.5 years). Mean duration from renal transplantation to the onset of PTLD was 7.1 years (range, 5 months to 18 years, 9 months). Mean duration of observation was 3.9 years from the onset of PTLD. Immunosuppressant therapy comprised multidrug combination therapy, including cyclosporine in six patients and tacrolimus in four patients. In addition to a reduction in the immunosuppressant dose, which was performed in all patients, PTLD was treated with surgery in seven patients, radiotherapy in two patients, rituximab in five patients, and cytotoxic chemotherapy in four patients. A complete remission in eight patients and progressive disease in two were observed. At last follow up, seven patients were alive and five patients had functioning grafts.Conclusions: The incidence of PTLD following renal transplantation at our institution is 1.6% with onset occurring more than 5 years after transplantation in five patients. Consequently, with long‐term renal graft survival now feasible, attention must be paid to detecting late‐onset PTLD.
- Retracted
- 21 October 2008
- Published by Springer Nature in Nature Clinical Practice Nephrology
- Vol. 4 (12) , 682-692
Japan's experience with living-donor kidney transplantation across ABO barriers
Nature Clinical Practice Nephrology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of topical issues throughout the year, with the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.
- 21 October 2008
- Published by Springer Nature in Nature Clinical Practice Nephrology
- Vol. 4 (12) , 682-692
RetractedJapan's experience with living-donor kidney transplantation across ABO barriers
Nature Clinical Practice Nephrology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of topical issues throughout the year, with the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.
- Open Access
- 28 June 2008
- Published by Wiley in International Journal of Urology
- Vol. 15 (7) , 587-592
Pregnancy after renal transplantation: A single‐center experience
Objectives: To examine women with renal transplants who became pregnant, and delivered at our hospital. Methods: Twenty‐six women who had undergone renal transplantation between 1977 and 2002 became pregnant, and delivered at Osaka University Hospital. Complete medical records of twenty of them were retrieved and retrospectively analyzed. Results: Overall, twenty‐nine pregnancies occurred in these twenty women after renal transplantation. There were spontaneous abortions in three cases, whereas pregnancy was artificially terminated five times. Thus, neonates were delivered in 21 of 29 pregnancies. One woman delivered twice and two women delivered twins. As a result, a total of 23 neonates were delivered. Mean gestational period was 35.4 weeks (range, 27–41 weeks), and mean birth weight was 2229 g (range, 724–3544 g). Regarding fetal complications, intrauterine growth retardation was observed in three cases. One child with intrauterine growth retardation died at 3 months old due to respiratory distress syndrome. One child displayed double‐outlet right ventricle and another child had congenital unilateral hydronephrosis. Regarding maternal complications, prevalence of toxemia of pregnancy was 38.1%. In four of the 21 deliveries (19.0%), renal function exacerbated after delivery. Rates of graft survival for the 20 women at 1, 5 and 10 years after delivery were 100%, 85.1% and 74.4%, respectively. Prognosis for renal transplant resulted to be significantly poorer for recipients with hypertension before pregnancy than for recipients without hypertension before pregnancy (log‐rank test, P = 0.043). Conclusions: Rates of graft survival after delivery were mostly favorable. However, prognosis for renal function was poorer for recipients who displayed hypertension prior to pregnancy.
- 28 June 2008
- Published by Wiley in International Journal of Urology
- Vol. 15 (7) , 587-592
Open AccessPregnancy after renal transplantation: A single‐center experience
Objectives: To examine women with renal transplants who became pregnant, and delivered at our hospital. Methods: Twenty‐six women who had undergone renal transplantation between 1977 and 2002 became pregnant, and delivered at Osaka University Hospital. Complete medical records of twenty of them were retrieved and retrospectively analyzed. Results: Overall, twenty‐nine pregnancies occurred in these twenty women after renal transplantation. There were spontaneous abortions in three cases, whereas pregnancy was artificially terminated five times. Thus, neonates were delivered in 21 of 29 pregnancies. One woman delivered twice and two women delivered twins. As a result, a total of 23 neonates were delivered. Mean gestational period was 35.4 weeks (range, 27–41 weeks), and mean birth weight was 2229 g (range, 724–3544 g). Regarding fetal complications, intrauterine growth retardation was observed in three cases. One child with intrauterine growth retardation died at 3 months old due to respiratory distress syndrome. One child displayed double‐outlet right ventricle and another child had congenital unilateral hydronephrosis. Regarding maternal complications, prevalence of toxemia of pregnancy was 38.1%. In four of the 21 deliveries (19.0%), renal function exacerbated after delivery. Rates of graft survival for the 20 women at 1, 5 and 10 years after delivery were 100%, 85.1% and 74.4%, respectively. Prognosis for renal transplant resulted to be significantly poorer for recipients with hypertension before pregnancy than for recipients without hypertension before pregnancy (log‐rank test, P = 0.043). Conclusions: Rates of graft survival after delivery were mostly favorable. However, prognosis for renal function was poorer for recipients who displayed hypertension prior to pregnancy.
- 1 June 2008
- Published by Elsevier in Transplantation Proceedings
- Vol. 40 (5) , 1362-1365
Treatment Adherence in Renal Transplant Recipients: A Questionnaire Survey on Immunosuppressants
- 1 June 2008
- Published by Elsevier in Transplantation Proceedings
- Vol. 40 (5) , 1362-1365
Treatment Adherence in Renal Transplant Recipients: A Questionnaire Survey on Immunosuppressants
- Open Access
- 1 February 2004
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 32 (1) , 45-52
Pharmacokinetics and Lipid-Lowering Effect of Fluvastatin in Hypercholesterolaemic Patients on Maintenance Haemodialysis
Patients undergoing haemodialysis are predisposed to serum lipid abnormalities that can accelerate the development of atherosclerosis. Serum lipid levels must therefore be controlled over a long period. For patients with reduced renal function (including dialysis patients), special attention must be paid to hyperlipidaemia therapy, particularly drug selection. In this study, 30 mg/day fluvastatin was administered orally to five patients receiving maintenance haemodialysis. Their serum lipid levels and blood biochemistry were monitored during the 6 months of fluvastatin administration, and the pharmacokinetic parameters calculated. The therapeutic efficacy and safety of fluvastatin were demonstrated in this patient group. Furthermore, fluvastatin is not influenced by the dialysis membrane and does not accumulate in haemodialysis patients with hyperlipidaemia.
- 1 February 2004
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 32 (1) , 45-52
Open AccessPharmacokinetics and Lipid-Lowering Effect of Fluvastatin in Hypercholesterolaemic Patients on Maintenance Haemodialysis
Patients undergoing haemodialysis are predisposed to serum lipid abnormalities that can accelerate the development of atherosclerosis. Serum lipid levels must therefore be controlled over a long period. For patients with reduced renal function (including dialysis patients), special attention must be paid to hyperlipidaemia therapy, particularly drug selection. In this study, 30 mg/day fluvastatin was administered orally to five patients receiving maintenance haemodialysis. Their serum lipid levels and blood biochemistry were monitored during the 6 months of fluvastatin administration, and the pharmacokinetic parameters calculated. The therapeutic efficacy and safety of fluvastatin were demonstrated in this patient group. Furthermore, fluvastatin is not influenced by the dialysis membrane and does not accumulate in haemodialysis patients with hyperlipidaemia.
- 1 October 2001
- Published by Elsevier in Atherosclerosis
- Vol. 158 (2) , 417-423
Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus
- 1 October 2001
- Published by Elsevier in Atherosclerosis
- Vol. 158 (2) , 417-423
Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus